Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Amazon, Warner Bros, and Dow rise premarket; Nio, Nike, HP fall

Published 2023/09/25, 13:48
© Reuters.
DIS
-
DOW
-
WBD
-
AMZN
-
AZN
-
HPQ
-
NKE
-
NFLX
-
NIO
-

Investing.com -- U.S. futures edged lower Monday, with investors still reeling from last week’s hawkish Federal Reserve meeting, while a U.S. government shutdown draws nearer.

Here are some of the biggest premarket U.S. stock movers today:

  • Amazon (NASDAQ:AMZN) stock rose 0.5% after the tech giant announced plans to invest up to $4 billion in artificial intelligence group Anthropic, in an attempt to bolster its position in nascent AI technology.

  • Warner Bros Discovery (NASDAQ:WBD) stock rose 2.1%, Netflix (NASDAQ:NFLX) rose 0.8% and Walt Disney (NYSE:DIS) rose 0.3% as these entertainment giants benefited from the news that Hollywood's writers union reached a preliminary labor agreement with major studios on Sunday, likely ending strikes that have halted most film and television production.

  • Nio (NYSE:NIO) ADRs fell 6.8% after the Chinese EV manufacturer announced it was considering raising $3B from investors.

  • Nike (NYSE:NKE) stock fell 1.4% after Jefferies downgraded the sportswear giant to ‘hold’ from ‘buy’, citing increased risk due to ongoing pressure on the wholesale channel and macroeconomic challenges in China.

  • HP (NYSE:HPQ) stock fell 3.7% after Warren Buffett's Berkshire Hathaway (NYSE:BRKa) sold nearly 4.8 million shares of the PC-maker.

  • Dow (NYSE:DOW) stock rose 1.4% after JPMorgan upgraded its stance on the chemicals giant the company to ‘overweight’ from ‘neutral’, citing a robust balance sheet, a hefty dividend yield and ample upside.

  • Rocket Companies (NYSE:RKT) stock rose 3.1% after CFRA upgraded the mortgage loan provider to ‘hold’ from ‘sell’, saying its diversified businesses and available liquidity resources position it well.

  • AstraZeneca (LON:AZN) (NASDAQ:AZN) ADRs rose 1.7% after Jefferies upgraded the pharmaceutical company to ‘buy’ from ‘neutral’, noting last week’s positive results from its new lung cancer drug.

  • Harmony Biosciences (NASDAQ:HRMY) stock fell 3.1% after Goldman Sachs downgraded the biopharmaceutical company to ‘sell’ from ‘neutral’, seeing emerging risks to the durability of its revenue stream.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.